Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072018 · ClinicalTrials.gov registry record · Phase 1
Peyronie's Disease Treatment Protocol
A Phase 1 study of Peyronie's Disease, sponsored by Hybrid Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT02072018: Completed Phase 1 study of Peyronie's Disease, sponsored by Hybrid Medical.
NCT02072018 is a Phase 1 study of Peyronie's Disease that has completed, run by Hybrid Medical. The registered enrollment target is 22 participants, below the 186-participant average among 5 other Peyronie's Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02072018, a Phase 1 study of Peyronie's Disease, has completed, sponsored by Hybrid Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Treatment of Peyronie's disease remains difficult. The purpose of this study is to test the safety and efficacy of a new compound to treat this disease.
Primary Outcome
Number of participants with adverse events. Continuous monitoring for adverse events. An adverse event is the development of an undesirable medical condition - e.g. symptoms or abnormal results of an investigation - or the deterioration of a pre-existing medical condition (not relevant in this study). Per the subject description, adverse events will be reported as: mild, moderate or severe.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG H-100
Study Locations (1)
Minnesota
- North Memorial Medical Center - Robbinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT02072018 record still lists
NCT02072018 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 186-participant average among 5 other Peyronie's Disease trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Peyronie's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02072018 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02072018 about?
NCT02072018 is a clinical study titled "Peyronie's Disease Treatment Protocol". Treatment of Peyronie's disease remains difficult. The purpose of this study is to test the safety and efficacy of a new compound to treat this disease.
What is the current status of trial NCT02072018?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2013-06. Estimated completion is 2013-12.
What conditions does trial NCT02072018 study?
This clinical trial studies the following conditions: Peyronie's Disease.
What interventions are being tested in trial NCT02072018?
The interventions under investigation include: Placebo (DRUG), H-100 (DRUG).
Who is sponsoring clinical trial NCT02072018?
This trial is sponsored by Hybrid Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02072018 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peyronie's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
ACTIVE NOT RECRUITING · Phase 4
-
Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's
ACTIVE NOT RECRUITING · Phase 4
-
Study of AA4500 in the Treatment of Peyronie's Disease
COMPLETED · Phase 3
-
H-22411: BOTOX® for Peyronie's Disease
COMPLETED · Phase 2
-
Study of AA4500 in the Treatment of Peyronie's Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia